论文部分内容阅读
目的观察厄贝沙坦联合辛伐他汀对充血性心力衰竭患者心功能的改善作用。方法选择安阳市第二人民医院2014年1月至2015年4月收治的89例充血性心力衰竭患者分为观察组(45例)与对照组(44例)。对照组应用辛伐他汀治疗,观察组联合厄贝沙坦与辛伐他汀。比较两组心功能疗效与治疗前后LVEF(左心室射血分数)、LVEDD(左心室舒张末期内径)、HR(心率)等心功能指标。结果观察组心功能改善有效率为93.3%,显著高于对照组(77.3%),比较差异有统计学意义(P<0.05)。两组治疗前各心功能指标的比较差异未见统计学意义(P>0.05),经治疗后两组各心功能指标均获得改善,组内前后对比差异有统计学意义(P<0.05);与此同时,经治疗后,观察组HR、LVEDD低于对照组,LVEF高于对照组,提示改善幅度更大,比较差异具有统计学意义(P<0.05)。结论厄贝沙坦联合辛伐他汀对充血性心力衰竭可有效改善HR、LVEDD、LVEF等心功能指标,提高心功能分级,心力衰竭进展得以延缓,同时安全性高,为理想的治疗方案。
Objective To observe the effect of irbesartan and simvastatin on cardiac function in patients with congestive heart failure. Methods The 89 patients with congestive heart failure admitted to the Second People’s Hospital of Anyang from January 2014 to April 2015 were divided into observation group (45 cases) and control group (44 cases). The control group was treated with simvastatin and the observation group combined with irbesartan and simvastatin. The cardiac function was compared between the two groups before and after treatment with LVEF (left ventricular ejection fraction), LVEDD (left ventricular end-diastolic diameter), HR (heart rate) and other cardiac function indicators. Results The improvement rate of heart function in observation group was 93.3%, which was significantly higher than that in control group (77.3%). There was significant difference between the two groups (P <0.05). There was no significant difference in each cardiac function index between the two groups before treatment (P> 0.05). After treatment, the indexes of cardiac function in both groups were improved. There was significant difference before and after treatment in both groups (P <0.05). At the same time, after treatment, the observation group HR, LVEDD lower than the control group, LVEF higher than the control group, suggesting that the magnitude of improvement is greater, the difference was statistically significant (P <0.05). Conclusion Irbesartan combined with simvastatin can improve cardiac function index such as HR, LVEDD and LVEF, improve heart function grading, delay the progression of heart failure and improve safety. It is an ideal treatment for congestive heart failure.